Phase 2RecruitingPriority 3 · Moderate priorityNCT05958719
Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma
Plain-language summary
This Phase 2 trial is comparing different first-line treatment approaches for people newly diagnosed with a type of T-cell lymphoma called AITL. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 18 Years or older
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Chidamide (DRUG): chidamide 30mg biw, p.o, 21 days for a cycle. | Azacitidine (DRUG): 75mg/m2, continuous i.h. on day 1-7，21 days for a cycle. | liposomal mitoxantrone (DRUG): 12mg/m2， d1,21 days for a cycle. | prednisone (DRUG): 60mg/m2，d1-5,21 days for a cycle.
- Drugs / treatments
- Chidamide, Azacitidine, liposomal mitoxantrone, prednisone
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details